{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:00Z","timestamp":1784869320640,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Essential hypertension is a leading cause of chronic kidney disease, but conventional renal markers detect injury only after substantial nephron loss. Urinary nephrin, a slit-diaphragm protein released during podocyte injury, has been proposed as an early biomarker of hypertensive nephropathy, yet stage-specific data are scarce, particularly from Central Asia. In this single-centre, prospective study, we enrolled 60 adults with essential hypertension stratified by stage (I, II, III;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920 per group) in Bukhara, Uzbekistan; patients with diabetes, heart failure, primary kidney disease, or prior SARS-CoV-2 infection were excluded. Urinary nephrin, serum cystatin-C, TGF-\n                    <jats:italic>\u03b2<\/jats:italic>\n                    1, aldosterone, and VEGF-A were measured by ELISA, and renal Doppler ultrasonography and an oral protein-loading test for renal functional reserve (RFR) were performed at baseline and after 6 months of an ACE inhibitor or angiotensin receptor blocker, with eplerenone where indicated. Urinary nephrin rose progressively across stages (91.9\u2009\u00b1\u20098.3, 124.9\u2009\u00b1\u20099.3, 164.5\u2009\u00b1\u20099.7\u2005ng\/mL) and was already elevated in stage I despite normal creatinine, cystatin-C, and eGFR. Nephrinuria correlated with systolic blood pressure (r\u2009=\u20090.58), aldosterone (r\u2009=\u20090.54), and microalbuminuria (r\u2009=\u20090.71), and inversely with eGFR (r\u2009=\u2009\u22120.74) and RFR (r\u2009=\u2009\u22120.76; all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&amp;lt;\u20090.01). After 6 months, urinary nephrin declined by 32%, 31%, and 23% across stages, with parallel reductions in TGF-\n                    <jats:italic>\u03b2<\/jats:italic>\n                    1, VEGF-A, and aldosterone and partial RFR recovery. Urinary nephrin is elevated while conventional markers remain normal and responds to nephroprotective therapy, supporting its potential as an early biomarker of hypertensive kidney injury.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1878203","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:01Z","timestamp":1784866981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary nephrin as an early biomarker of podocyte dysfunction in essential hypertension: a stage-stratified study from Bukhara, Uzbekistan"],"prefix":"10.3389","volume":"13","author":[{"given":"Mukhammad Komil ogli","family":"Amonov","sequence":"first","affiliation":[{"name":"Department of Faculty and Hospital Therapy, Bukhara State Medical Institute named after Abu Ali ibn Sino","place":["Bukhara, Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","volume-title":"Hypertension Fact Sheet","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5195\/cajgh.2018.321","article-title":"Burden of cardiovascular diseases in Central Asia","volume":"7","author":"Aringazina","year":"2018","journal-title":"Cent Asian J Glob Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/epidemiologia7010010","article-title":"Cardiovascular disease burden in rural Central Asia: a systematic review of epidemiological trends and mortality patterns","volume":"7","author":"Kassymkhan","year":"2026","journal-title":"Epidemiologia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1797882","DOI":"10.3389\/frhs.2026.1797882","article-title":"Thrombolysis use in STEMI patients in Central Asia: lessons from the Bukhara region of Uzbekistan","volume":"6","author":"Aslonova","year":"2026","journal-title":"Front Health Serv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1517\/14656566.2010.485612","article-title":"Hypertensive nephropathy: prevention and treatment recommendations","volume":"11","author":"Hart","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e92949","DOI":"10.7759\/cureus.92949","article-title":"Hypertensive nephrosclerosis: pathological changes and overlap with diabetic nephropathy","volume":"17","author":"Qasim","year":"2025","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/HJH.0000000000001170","article-title":"Hypertensive nephropathy: moving from classic to emerging pathogenetic mechanisms","volume":"35","author":"Seccia","year":"2017","journal-title":"J Hypertens"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2478\/amb-2024-0049","article-title":"Diagnostic accuracy of microalbuminuria in secondary nephropathies","volume":"51","author":"Kostovska","year":"2024","journal-title":"Acta Med Bulg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jsha.2015.12.003","article-title":"Microalbuminuria is a late event in patients with hypertension: do we need a lower threshold?","volume":"29","author":"Wahab","year":"2017","journal-title":"J Saudi Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/14737159.2020.1768849","article-title":"Cystatin C as a biomarker of chronic kidney disease: latest developments","volume":"20","author":"Benoit","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.12998\/wjcc.v7.i22.3698","article-title":"Human podocyte injury in the early course of hypertensive renal injury","volume":"7","author":"Sun","year":"2019","journal-title":"World J Clin Cases"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2050-7771-2-21","article-title":"Nephrin \u2014 a biomarker of early glomerular injury","volume":"2","author":"Kandasamy","year":"2014","journal-title":"Biomark Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10157-024-02465-y","article-title":"Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases","volume":"28","author":"Fukuda","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"F1084","DOI":"10.1152\/ajprenal.00597.2011","article-title":"Increased urinary excretion of nephrin, podocalyxin, and \u03b2ig-h3 in women with preeclampsia","volume":"302","author":"Wang","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.6026\/973206300213123","article-title":"Urinary nephrin \u2014 an emerging novel biomarker in early detection of diabetic nephropathy: a review","volume":"21","author":"Sateesh","year":"2025","journal-title":"Bioinformation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1021\/acs.jproteome.4c00751","article-title":"Development of a multiplexed LC-MS\/MS assay for the quantitation of podocyte injury biomarkers nephrin, podocalyxin, and podocin in human urine","volume":"24","author":"Morales-Betanzos","year":"2025","journal-title":"J Proteome Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.3390\/jcm13123432","article-title":"Urine nephrin and podocalyxin reflecting podocyte damage and severity of kidney disease in various glomerular diseases \u2014 a cross-sectional study","volume":"13","author":"Giannou","year":"2024","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1097\/HJH.0000000000001747","article-title":"Urinary podocyte-associated molecules and albuminuria in hypertension","volume":"36","author":"Perez-Hernandez","year":"2018","journal-title":"J Hypertens"},{"key":"B22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4155\/fmc-2020-0005","article-title":"TGF-\u03b2 in renal fibrosis: triumphs and challenges","volume":"12","author":"Gu","year":"2020","journal-title":"Future Med Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"B25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10157-008-0034-9","article-title":"Aldosterone and glomerular podocyte injury","volume":"12","author":"Nagase","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF Inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0002-9149(00)01512-5","article-title":"Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension","volume":"87","author":"Belgore","year":"2001","journal-title":"Am J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"B30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000363721","article-title":"Renal functional reserve and renal recovery after acute kidney injury","volume":"127","author":"Sharma","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1080\/0886022X.2016.1214052","article-title":"Renal functional reserve and renal hemodynamics in hypertensive patients","volume":"38","author":"Gaipov","year":"2016","journal-title":"Ren Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/HJH.0b013e328365b29c","article-title":"Ultrasound Doppler renal resistive index: a useful tool for the management of the hypertensive patient","volume":"32","author":"Viazzi","year":"2014","journal-title":"J Hypertens"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1093\/ndt\/10.11.2060","article-title":"The pulsatility index and the resistive index in renal arteries in patients with hypertension and chronic renal failure","volume":"10","author":"Petersen","year":"1995","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1878203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:03Z","timestamp":1784866983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1878203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2026.1878203"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1878203","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1878203"}}